 CAMBRIDGE, Mass., June 14, 2021 GLOBE NEWSWIRE -- Cue Biopharma, Inc. Nasdaq: CUE, a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patients body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held June 16-17, 2021. 